Deciphera Pharmaceuticals has been granted a patent for a low impurity pharmaceutical composition containing a specific compound for treating disorders related to c-KIT and PDGFRa kinases. The composition is designed for oral delivery. GlobalData’s report on Deciphera Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Deciphera Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Deciphera Pharmaceuticals's grant share as of February 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent (Publication Number: US11918564B1) discloses a pharmaceutical composition designed for the oral delivery of a compound represented by Formula (I). The composition includes a solid dispersion containing an amorphous form of the compound, ensuring efficient delivery and absorption in the body.
Furthermore, the pharmaceutical composition may also include one or more pharmaceutically acceptable carriers along with the solid dispersion. This combination enhances the stability and bioavailability of the compound represented by Formula (I) when administered orally. Additionally, a specific embodiment of the composition includes 50 mg of the compound in its amorphous form within the solid dispersion, highlighting a precise dosage for effective delivery.
To know more about GlobalData’s detailed insights on Deciphera Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.